Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | China | 2015
How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…
The Evolving Market Access Landscape for Spondyloarthritis | Physician & Payer Forum | EU5 | 2015
Physician and Payer Perspectives on Biologic Use and Novel Therapeutic Targets in the Treatment of Psoriatic Arthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis…
Market Access Opportunities and Challenges in Rheumatoid Arthritis | Physician & Payer Forum | EU5 | 2015
A Survey of Rheumatologists and Interviews with Payers in the EU5 Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that…
Crohn’s Disease and Ulcerative Colitis (Market Access Landscape) | Physician & Payer Forum | EU5 | 2015
Payer and Physician Perspectives on the Role of New Biologics and Biosimilars for Moderate to Severe Inflammatory Bowel Disease Moderate to severe inflammatory bowel disease (IBD) patients who…
Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | Brazil/Mexico | 2015
How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…
The Impact of Biosimilars in NHL, Breast Cancer, and Colorectal Cancer | Physician & Payer Forum | Brazil and Mexico | 2015
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
EU5 Market Access Opportunities and Challenges for Current and Emerging Rheumatoid Arthritis Agents Amid the Launches of Oral Jak Inhibitors and Biosimilars | Physician & Payer Forum | EU5 | 2014
Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that typically results in permanent, debilitating tissue damage. Biological…
Psoriasis (How Will the Launches of Efficacious Biologics and Novel Oral Agents Affect Psoriasis Treatment and Reimbursement? Insights from U.S. Physicians and Payers) | US | 2014
Psoriasis is a chronic inflammatory skin disorder that is managed with systemic therapies for moderate to severe patients who fail first-line topical therapies and/or phototherapy. Dermatologists…
Physician &Crohn’s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars | Payer Forum | US | 2014
Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market…
